Evidence map›Paper›PMID 40149338›Full record

ArticleCancers2025

Investigating Intensity and Percentage of p53 Nuclear Expression in Prostate Cancer: Findings from a Cohort of U.S. Military Veterans.

William R Gesztes, Coen J Lap, Rithika Rajendran, Maryam M Dalivand, Guoqing Diao, Shanshan Liu, Maneesh Jain, Victor E Nava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William R GesztesDepartment of Pathology, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0001-6735-7125
Coen J LapThe Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0001-6815-0695
Rithika RajendranDepartment of Pathology, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0001-6006-176X
Maryam M DalivandDepartment of Pathology, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0003-2671-6325
Guoqing DiaoDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, DC 20037, USA.
Shanshan LiuDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, DC 20037, USA.
Maneesh JainThe Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0002-4394-3055
Victor E NavaDepartment of Pathology, Washington DC VA Medical Center, Washington, DC 20422, USA.ORCID 0000-0002-1438-9665

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748Prostate Cancer Foundation 1651999-19
6 · The paper itself

Abstract

backgroundNext-generation sequencing has revealed

methodsThis study included 84 patients (75% self-identified as African American) diagnosed with PCa between 1996 and 2021 at the DC VA Medical Center. Representative sections of core biopsies, radical prostatectomies, transurethral prostate resections, and metastatic deposits were examined. p53 nuclear expression was scored according to the highest intensity observed (0, 1+, 2+, 3+) and the percentage (0%, <1%, 1-5%, >5%) of tumor cells expressing any level of intensity in the aggregate tumor area. All slides were reviewed by two independent pathologists. Pertinent clinical data were collected.

resultsA total of 34 patients (40%) exhibited p53 nuclear expression, of which 18 (21%) showed the maximum (3+) intensity. The presence of maximum intensity, regardless of percentage, was found to be associated with Grade Group (

conclusionsMaximum (3+) p53 nuclear intensity of any percentage is highly associated with disease progression in PCa, suggesting that optimal determination of p53 overexpression should incorporate intensity.

Indexed as

African Americanbiomarkerimmunohistochemistryp53progressionprostate cancerTP53

Identifiers

PMID40149338
PMCPMC11941523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.